INSPIRE PHARM (NASDAQ:ISPH)
5.04
+0.02 (0.40%)
| INSPIRE PHARM (NASDAQ:ISPH) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $5.02 | 52 Week High | $6.54 | ||
| Open | $4.96 | 52 Week Low | $2.59 | ||
| Day High | $5.28 | P/E | N/A | ||
| Day Low | $4.96 | EPS | $-0.80 | ||
| Volume | 401,960 | ||||
| More ISPH Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| AMS | 1 | BSTC | 1 |
| CVCO | 1 | FUR | 1 |
| HRP | 1 | KID | 1 |
| MGM | 1 | OCR | 1 |
| RGLD | 1 | SMTX | 1 |
| TUC | 1 | ZINC | 1 |
Entities who have mentioned ISPH
- Carl Icahn | View Related Stories »
- SAC Capital | View Related Stories »
- Steven A. Cohen | View Related Stories »
- Wedbush Morgan | View Related Stories »
- Initial Jobless Claims | View Related Stories »
- GLG Partners | View Related Stories »
- Trading Radar | View Related Stories »
- Life, Style and Real Estate | View Related Stories »
- Collins Stewart | View Related Stories »
- Citi | View Related Stories »
- Piper Jaffray | View Related Stories »
- Morgan Stanley | View Related Stories »
- Deutsche Bank | View Related Stories »
View All Major News StreetInsider.com Major News for ISPH
- Inspire Pharma (ISPH) posts Q3 Loss of $0.12, Bests By 3c
- Inspire Pharmaceuticals (ISPH) Reports Q2 EPS In-Line
- Inspire Pharma (ISPH) Reports Q4 Loss of $0.17; Guides FY09 Sales
View All ReportsStreetInsider.com Reports on ISPH
- Inspire Pharma (ISPH) posts Q3 Loss of $0.12, Bests By 3c
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
- Wedbush Morgan Downgrades Inspire Pharmaceuticals (ISPH) to Neutral
- Inspire Pharma (ISPH) Committed to Helping Healthcare Providers and Patients During Erythromycin Ophthalmic Ointment Shortage
- Inspire Pharmaceuticals (ISPH) Prices 22.2M Shares at $4.50/Sh
View All Press ReleasesCompany Press Releases on ISPH
- Inspire Reports Third Quarter 2009 Financial Results
- Inspire Completes Patient Enrollment in Three Late-Stage Clinical Trials in Cystic Fibrosis, Dry Eye and Blepharitis
- Inspire Announces Date for Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results
- Inspire's President and CEO Christy Shaffer Receives Cystic Fibrosis Foundation's Highest Award
- Inspire Announces Presentation at the North American Cystic Fibrosis Conference and Provides Enrollment Update for Phase 3 Cystic Fibrosis Trial
StreetInsider Reports on ISPH by Category
View All BlogsBlogs on ISPH
- Biotech Discounts Galore
- Inspire Pharmaceuticals, Inc. Q2 2009 Earnings Call Transcript
- Analyst upgrades, downgrades and initiations: MS, JCG, BKC, LVLT, NWS ...
- Inspire Pharma Still Looks Good After Earnings
- Inspire Pharmaceuticals, Inc. Q1 2009 Earnings Call Transcript
View All FilingsSEC Filings on ISPH
- Form 4 INSPIRE PHARMACEUTICALS For: Nov 11 Filed by: Brazzell Romulus K
- Form 4 INSPIRE PHARMACEUTICALS For: Nov 11 Filed by: SHAFFER CHRISTY L
- Form 4 INSPIRE PHARMACEUTICALS For: Nov 11 Filed by: SCHACHLE JOSEPH K
- Form 4 INSPIRE PHARMACEUTICALS For: Nov 11 Filed by: Spagnardi Joseph M
- Form 4 INSPIRE PHARMACEUTICALS For: Nov 11 Filed by: STAAB THOMAS R II
Comments on recent ISPH articles
Comments on ISPH
No comments are currently available.
on Feb 20, 2008
at 03:42 PM INSM A $3.00 dollar stock trading below a $1.00.
Article: Analyst Call of the Year: Collins Stewart on Encysive (ENCY)